TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18325770

Group type: EXPERIMENTAL
Intervention: Posterior cruciate-substituting (PS) TKA
Number of subjects: 192

Group type: COMPARATOR
Intervention: Posterior cruciate-retaining (CR) TKA
Number of subjects: 192
Study: 16844891

Group type: EXPERIMENTAL
Intervention: Medication-randomized clinical trial scenario
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Neurosurgical clinical trial scenario
Number of subjects: 99
Study: 12911356

Group type: EXPERIMENTAL
Intervention: Single-use bougie
Number of subjects: 32

Group type: COMPARATOR
Intervention: Multiple-use bougie
Number of subjects: 32
Study: 10831902

Group type: EXPERIMENTAL
Intervention: Immunotoxin MDX‐RA (low dose: 50 units)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Immunotoxin MDX‐RA (high dose: 100 units)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9393916

Group type: EXPERIMENTAL
Intervention: Flexible intramedullary nailing (FIN)
Number of subjects: 19

Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 19
Study: 7894066

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Interruption of hypertension therapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Family history of stroke
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Long working hours
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overwork
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Difficulty of taking a day-off each week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Preference for salty taste
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Habitual drinking
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: High blood pressure (from mass health examination data)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Serum cholesterol (from mass health examination data)
Number of subjects: 62
Study: 3128589

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium by MDI (1 mg per actuation)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo by MDI
Number of subjects: 155
Study: 31007059

Group type: EXPERIMENTAL
Intervention: Muscle Cramp Scale (MCS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Muscle Cramp Scale (MCS) and cramp diary
Number of subjects: 56
Study: 27704296

Group type: EXPERIMENTAL
Intervention: aPDT (low power laser: 660 nm, 40 mW, 90 J/cm2, methylene blue 0.01%) performed at baseline and 3, 6, and 9 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 28
Study: 27986741

Group type: EXPERIMENTAL
Intervention: CBM‐I with prior RNT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CBM‐I without prior RNT (standard CBM‐I)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Active control (no resolution of ambiguity)
Number of subjects: 120
Study: 24643920

Group type: EXPERIMENTAL
Intervention: Desflurane (group D, n = 32)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol (group P, n = 28)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desflurane (group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol (group P)
Number of subjects: 60
Study: 22002175

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 or 200 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 19224159

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus intravenous supplementation with omega‐3 fish oil emulsion 0.2 g/kg every day (FO group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus intravenous supplementation with omega‐3 fish oil emulsion (FO group)
Number of subjects: 60
Study: 17300356

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 15149252

Group type: EXPERIMENTAL
Intervention: Depressed participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondepressed control participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depressed participants vs. older participants
Number of subjects: 0
Study: 12149668

Group type: EXPERIMENTAL
Intervention: Lercanidipine tablets 10 mg once-daily (n = 234)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Losartan tablets 50 mg once-daily (n = 231)
Number of subjects: 465
Study: 9862408

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Saline placebo nasal spray
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray and nicotine gum
Number of subjects: 91
Study: 8548940

Group type: COMPARATOR
Intervention: rhGH (0.0675 IU/kg, 3 times/week)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rhGH + Pamidronate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 21
Study: 2167109

Group type: EXPERIMENTAL
Intervention: Total hip replacement surgery
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Thrombi location analysis
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Thrombus characteristics
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Types of thrombosis
Number of subjects: 122
Study: 320856

Group type: EXPERIMENTAL
Intervention: Vitamin E (1,600 I.U. of d-alpha-tocopherol succinate daily) for 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo therapy for 6 months
Number of subjects: 48
Study: 7030221

Group type: EXPERIMENTAL
Intervention: Aero-chamber with fenoterol (beta 2 stimulant)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard aerosol inhaler with placebo
Number of subjects: 10
Study: 31925473

Group type: EXPERIMENTAL
Intervention: 12-week multicomponent exercise programme
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 149
Study: 30203225

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sofosbuvir-velpatasvir plus ribavirin for 12 weeks
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sofosbuvir-velpatasvir plus ribavirin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sofosbuvir-velpatasvir and ribavirin
Number of subjects: 102
Study: 28578841

Group type: EXPERIMENTAL
Intervention: 10% off-the-shelf Povidone-Iodine (PI)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: 5% Povidone-Iodine-based Skin and Nasal Antiseptic (SNA)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 429
Study: 26493088

Group type: COMPARATOR
Intervention: Standard lumbar spine imaging reports
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Reports containing prevalence data for common imaging findings in patients without back pain
Number of subjects: 100
Study: 23380074

Group type: EXPERIMENTAL
Intervention: Mouthwash containing 0.8% arginine, PVM/MA copolymer, pyrophosphates, and 0.05% sodium fluoride
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Mouthwash containing 2.4% potassium nitrate and 0.022% sodium fluoride
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control mouthwash containing 0.05% sodium fluoride
Number of subjects: 75
Study: 22093205

Group type: EXPERIMENTAL
Intervention: Adjusted dose eptifibatide (1 μg/kg/min; eCrCl <50 ml/min)
Number of subjects: 8708

Group type: EXPERIMENTAL
Intervention: Excess dose eptifibatide (2 μg/kg/min; eCrCl <50 ml/min)
Number of subjects: 8708

Group type: COMPARATOR
Intervention: Early provisional treatment
Number of subjects: 8708

Group type: COMPARATOR
Intervention: Delayed provisional treatment
Number of subjects: 8708
Study: 19520472

Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention
Number of subjects: 267

Group type: COMPARATOR
Intervention: Usual care for orphaned children
Number of subjects: 267
Study: 17588225

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg p.o.) with reboxetine (4 mg p.o.)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (no hydrocortisone or reboxetine)
Number of subjects: 54
Study: 15167872

Group type: EXPERIMENTAL
Intervention: Transabdominal light stimulation
Number of subjects: 107

Group type: COMPARATOR
Intervention: No light stimulation
Number of subjects: 107
Study: 12401010

Group type: EXPERIMENTAL
Intervention: Universal femoral components
Number of subjects: 101

Group type: COMPARATOR
Intervention: Anatomic femoral components
Number of subjects: 101

Group type: COMPARATOR
Intervention: External rotation of the femoral component
Number of subjects: 101
Study: 10103294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Maintenance dose of stimulant medication
Number of subjects: 19
Study: 7788958

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg or 500 mg b.i.d.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cefaclor 250 mg or 500 mg t.i.d.
Number of subjects: 197
Study: 1979797

Group type: EXPERIMENTAL
Intervention: Antihistamines (specific type not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 0
Study: 417365

Group type: EXPERIMENTAL
Intervention: Baclofen (20‐120 mg daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31669329

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (7 monthly injections)
Number of subjects: 202
Study: 31389581

Group type: EXPERIMENTAL
Intervention: B-ultrasound-guided puncture treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ceftazidime and tinidazole (control group)
Number of subjects: 116
Study: 28552710

Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation with leuprorelin (Eligard®) for 36 months
Number of subjects: 701
Study: 26068865

Group type: EXPERIMENTAL
Intervention: Basal insulin with a prandial GLP-1 receptor agonist (GLIPULIN)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Basal-bolus insulin (BBI)
Number of subjects: 102
Study: 24368463

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy plus amitriptyline
Number of subjects: 135

Group type: COMPARATOR
Intervention: Headache education plus amitriptyline
Number of subjects: 135
Study: 21446795

Group type: EXPERIMENTAL
Intervention: Thermoplastic casts and plastic cups
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Three-dimensional technique
Number of subjects: 12

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 12
Study: 19427159

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Magnesium
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Morphine+Magnesium
Number of subjects: 105
Study: 16415311

Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 234
Study: 15776849

Group type: EXPERIMENTAL
Intervention: Surgical ventricular restoration (SVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary bypass alone
Number of subjects: 0
Study: 12414003

Group type: EXPERIMENTAL
Intervention: 2 mL of 2% plain lignocaine
Number of subjects: 110

Group type: COMPARATOR
Intervention: 2 mL of 0.9% sodium chloride solution (placebo)
Number of subjects: 110
Study: 9797057

Group type: EXPERIMENTAL
Intervention: Root form bioactive glass cones in bone splitting (BS) group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Root form bioactive glass cones in fresh extraction sockets (FES) group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (C) with conventional extraction sockets
Number of subjects: 16
Study: 7611396

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 20
Study: 2236458

Group type: EXPERIMENTAL
Intervention: Clomipramine (mean dosage 165 +/- 19 mg/day, reduced from 270 +/- 20 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clomipramine (initial dosage 270 +/- 20 mg/day)
Number of subjects: 10
Study: 78260

Group type: EXPERIMENTAL
Intervention: Simple mastectomy combined with radical radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple mastectomy alone
Number of subjects: 0
Study: 29476416

Group type: EXPERIMENTAL
Intervention: Nursing case-management intervention over 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27430425

Group type: EXPERIMENTAL
Intervention: sarolaner (Simparica™ Chewables) administered monthly for 3 months (2 to 4 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: fluralaner (Bravecto®) administered as a single dose (25 to 56 mg/kg)
Number of subjects: 24
Study: 23085086

Group type: EXPERIMENTAL
Intervention: Alpha binaural beat of 10 Hz
Number of subjects: 22

Group type: COMPARATOR
Intervention: Beta binaural beat of 20 Hz
Number of subjects: 22
Study: 22033712

Group type: EXPERIMENTAL
Intervention: GDC
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Matrix coils
Number of subjects: 517
Study: 20426626

Group type: EXPERIMENTAL
Intervention: Leukocyte telomere repeat copy number to single gene copy number (TSR)
Number of subjects: 518
Study: 17608868

Group type: EXPERIMENTAL
Intervention: Computerized alert system for pharmacists (intervention group)
Number of subjects: 59840

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 59840
Study: 15649674

Group type: EXPERIMENTAL
Intervention: Training to increase collaboration between general practitioners and occupational health physicians
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 112
Study: 11863106

Group type: EXPERIMENTAL
Intervention: Biennial fecal occult blood screening (FOBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Annual fecal occult blood screening (FOBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening mentioned)
Number of subjects: 0
Study: 10502861

Group type: EXPERIMENTAL
Intervention: Computer monitor tachistoscopes (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional tachistoscopes
Number of subjects: 0
Study: 7548266

Group type: EXPERIMENTAL
Intervention: Gallopamil 150 mg daily
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg tid for 28 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 34
Study: 1949361

Group type: EXPERIMENTAL
Intervention: Robinson gravity system
Number of subjects: 140

Group type: COMPARATOR
Intervention: Redon drainage system
Number of subjects: 140
Study: 7036825

Group type: EXPERIMENTAL
Intervention: 1 g daily intake of oral erythromycin base
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31436295

Group type: EXPERIMENTAL
Intervention: LC-TOF-MS method for GP screening
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: LC-TOF-MS method for PGL screening
Number of subjects: 1091

Group type: EXPERIMENTAL
Intervention: LC-MS-MS confirmation testing for GP and PGL
Number of subjects: 1091

Group type: COMPARATOR
Intervention: LC-MS-MS testing of previously negative specimens
Number of subjects: 1091
Study: 29059277

Group type: EXPERIMENTAL
Intervention: Active referral group
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Brief advice group
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1226
Study: 24571261

Group type: EXPERIMENTAL
Intervention: ERT combined with PVP
Number of subjects: 137

Group type: COMPARATOR
Intervention: ERT
Number of subjects: 137

Group type: COMPARATOR
Intervention: PVP
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 137
Study: 24933720

Group type: EXPERIMENTAL
Intervention: High reward (HR)
Number of subjects: 10
Study: 22448255

Group type: EXPERIMENTAL
Intervention: Well Woman Exam (WWE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 Educational Sessions (4ES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard intervention (SI)
Number of subjects: 0
Study: 21085661

Group type: EXPERIMENTAL
Intervention: Tetris
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pub Quiz
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-task control
Number of subjects: 0
Study: 17617940

Group type: EXPERIMENTAL
Intervention: 2.3 g/d plant sterol supplementation
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: 1.5 g/d plant sterol supplementation
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 16364999

Group type: EXPERIMENTAL
Intervention: Intervention group (n=35)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 75
Study: 12162476

Group type: EXPERIMENTAL
Intervention: gatifloxacin (400 mg po 1 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: oxycodone (5 mg po Q4H)
Number of subjects: 12

Group type: COMPARATOR
Intervention: gatifloxacin/oxycodone regimen
Number of subjects: 12
Study: 10658860

Group type: EXPERIMENTAL
Intervention: Massage therapy (n = 14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Music therapy (n = 16)
Number of subjects: 30
Study: 7604800

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bezafibrate 400 mg once daily
Number of subjects: 40
Study: 1481703

Group type: EXPERIMENTAL
Intervention: Implicit preparation instruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit preparation instruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random presentation mode of preparation intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked presentation mode of preparation intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of implicit/explicit instructions and random/blocked presentation modes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both procedural variables (implicit/explicit instructions and presentation modes)
Number of subjects: 0
Study: 3969867

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 10 mg every 2 hours for 72 hours
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41
Study: 30048216

Group type: EXPERIMENTAL
Intervention: Telephone-based follow-up (TFU)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 82
Study: 28383294

Group type: EXPERIMENTAL
Intervention: Billroth II (B‐II)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Roux-en-Y (R‐Y)
Number of subjects: 162
Study: 26878788

Group type: EXPERIMENTAL
Intervention: Wine polyphenol intake (WPI; 733 equivalents of gallic acid/day) for 28 days
Number of subjects: 57
Study: 26250580

Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone
Number of subjects: 0
Study: 23312690

Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 176
Study: 20875945

Group type: EXPERIMENTAL
Intervention: Working Group's Autobiographical Memory Test (initial evaluation)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Working Group's Autobiographical Memory Test (follow-up evaluation)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Working Group's Autobiographical Memory Test (test items)
Number of subjects: 63
Study: 18363889

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg for 4 days)
Number of subjects: 24
Study: 16797384

Group type: EXPERIMENTAL
Intervention: Nutrition intervention targeting specific barriers (e.g., poor nutritional knowledge, help needed with shopping or cooking, difficulty swallowing)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nutrition intervention targeting specific barriers
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 180
Study: 12941041

Group type: EXPERIMENTAL
Intervention: HRT (n = 122)
Number of subjects: 248

Group type: COMPARATOR
Intervention: No substitution (Control group, n = 126)
Number of subjects: 248
Study: 12212131

Group type: EXPERIMENTAL
Intervention: New mode CS (peritoneum not sewed)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: New mode CS (peritoneum sewed)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Lower segmental CS
Number of subjects: 468
Study: 9200994

Group type: EXPERIMENTAL
Intervention: Unrelated BMT
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Allogeneic-related BMT
Number of subjects: 96

Group type: COMPARATOR
Intervention: Autologous BMT
Number of subjects: 96
Study: 8427238

Group type: EXPERIMENTAL
Intervention: Protein‐sparing modified fast diet (2520 to 3360 J)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hypocaloric balanced diet (3360 to 4200 J)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both diets combined
Number of subjects: 19
Study: 3118061

Group type: EXPERIMENTAL
Intervention: Sterile gauze, replaced every other day
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: Gauze
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: Transparent polyurethane dressing
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: Iodophor-transparent dressing
Number of subjects: 2088
Study: 26460106

Group type: EXPERIMENTAL
Intervention: Felt stigma scale (8-item scale)
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Enacted stigma scale (4-item scale)
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Both stigma scales
Number of subjects: 1184
Study: 26011241

Group type: EXPERIMENTAL
Intervention: ORC/collagen matrix plus foam dressing (TIELLE®)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Foam dressing (TIELLE®)
Number of subjects: 33
Study: 24645966

Group type: COMPARATOR
Intervention: Single-dose (PEG 4 L the day before the study)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Split-dose (2 L the day before and 2 L on the day of the procedure)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Low-volume (2 L PEG solution the day of the procedure)
Number of subjects: 180
Study: 22453319

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60